Home/COVID-19 환자들의 심혈관 위험 관리

COVID-19 환자들의 심혈관 위험 관리

COVID-19
최신 관점
10 July 2020

이 웨비나는 감염의 기도 징후와 증상이 없는 COVID-19 환자들에서 어떻게 급성 심근염으로 인한 심장 침범이 발생할 수 있는지에 관해 설명할 것입니다.  

이 웨비나에 참석하면 다음 주제에 대한 이해를 높일 수 있을 것입니다. 

  1. COVID-19 감염 시 심장 생체표지자 상승의 잠재적 기전
  2. COVID-19 환자들에서 검사해야 할 생체표지자 및 심혈관 질환 진단 시점 
  3. COVID-19 환자 관리에서 심장 생체표지자의 가치 
Home/COVID-19患者の心血管リスク管理

COVID-19患者の心血管リスク管理

COVID-19
Latest Perspectives
10 July 2020

Key Takeaways

  • COVID-19は、新型コロナウイルス（SARS-CoV2）を原因とする全身性の疾患です。炎症や多臓器不全に加え、心臓のストレスと障害が誘発される症例も多くみられます。
  • COVID-19には、血液学的マーカー、炎症性マーカー、血栓性マーカーおよび循環器バイオマーカーの異常が伴います。
  • ヒト脳性ナトリウム利尿ペプチド前駆体N端フラグメント（NT-proBNP）とhs-Tnの異常値は、必ずしも心不全および急性心筋梗塞を反映したものとは限りません。
  • 循環器バイオマーカーの上昇は、COVID-19患者のトリアージと管理ならびに画像検査を含む臨床での意思決定に役立つ可能性があります。

このウェビナーでは、気道感染の徴候や感染の症状を伴わないCOVID-19患者において、急性心筋炎による心臓の障害がどのように現れるかを明らかにします。  

本ウェビナーに参加することで、以下の内容に関する理解を深めることができます。 

  1. COVID-19感染による循環器バイオマーカー上昇の原因として想定される機序
  2. COVID-19患者における心血管疾患の診断で検査すべきバイオマーカーとその検査時期 
  3. COVID-19患者の管理における循環器バイオマーカーの有用性 
Home/Management of Cardiovascular Risks of COVID-19 Patients

Management of Cardiovascular Risks of COVID-19 Patients

COVID-19
Latest Perspectives
Dr James L Januzzi Cardiologist, Massachusetts General Hospital. Prof of Medicine, Harvard Medical School
10 July 2020

Key Takeaways

  • COVID-19 is a systemic disease caused by novel corona SARS-CoV2 virus. It causes inflammation, multi organ failure and in many cases cardiac stress and injury
  • COVID-19 is associated with abnormal hemotological, inflammatory, thrombotic and cardiac biomarkers
  • Abnormal levels of NT-proBNP and hs-Tn do not necessarily reflect Heart Failure and Acute Myocardial Infarction
  • Elevation in the cardiac biomarkers might help in clinical decision making including triage and management as well as imaging in COVID-19 patients

This webinar will shed light on how cardiac involvement due to acute myocarditis may occur in patients with COVID-19 without respiratory tract signs and symptoms of infection.  

By attending this webinar you will come away with a greater understanding of : 

  1. The potential mechanisms underlying cardiac biomarkers elevation with COVID-19 infections
  2. What biomarkers should be tested and when for the diagnosis of cardiovascular conditions in COVID-19 patients 
  3. Value of cardiac biomarkers in COVID-19 patient management 

The information contained in Cardio ThinkLab is intended for healthcare professionals only.
Click "OK" if you are a healthcare professional.

OK

Want to receive the latest updates?